Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study
- PMID: 19969427
- PMCID: PMC2821955
- DOI: 10.1016/j.drugalcdep.2009.10.017
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study
Abstract
Objective: COMBINE is the largest study of pharmacotherapy for alcoholism in the United States to date, designed to answer questions about the benefits of combining behavioral and pharmacological interventions. Trajectory-based analyses of daily drinking data allowed identification of distinct drinking trajectories in smaller studies and demonstrated significant naltrexone effects even when primary analyses on summary drinking measures were unsuccessful. The objective of this study was to replicate and refine trajectory estimation and to assess effects of naltrexone, acamprosate and therapy on the probabilities of following particular trajectories in COMBINE. It was hypothesized that different treatments may affect different trajectories of drinking.
Methods: We conducted exploratory analyses of daily indicators of any drinking and heavy drinking using a trajectory-based approach and assessed trajectory membership probabilities and odds ratios for treatment effects.
Results: We replicated the trajectories ("abstainer", "sporadic drinker", "consistent drinker") established previously in smaller studies. However, greater numbers of trajectories better described the heterogeneity of drinking over time. Naltrexone reduced the chance to follow a "nearly daily" trajectory and Combined Behavioral Intervention (CBI) reduced the chance to be in an "increasing to nearly daily" trajectory of any drinking. The combination of naltrexone and CBI increased the probability of membership in a trajectory in which the frequency of any drinking declined over time. Trajectory membership was associated with different patterns of treatment compliance.
Conclusion: The trajectory-analyses identified specific patterns of drinking that were differentially influenced by each treatment and provided support for hypotheses about the mechanisms by which these treatments work.
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Figures






Similar articles
-
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.Alcohol Clin Exp Res. 2011 Mar;35(3):523-31. doi: 10.1111/j.1530-0277.2010.01369.x. Epub 2010 Dec 8. Alcohol Clin Exp Res. 2011. PMID: 21143249 Free PMC article. Clinical Trial.
-
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.Alcohol. 2012 Mar;46(2):121-31. doi: 10.1016/j.alcohol.2011.08.008. Epub 2011 Sep 17. Alcohol. 2012. PMID: 21925828 Free PMC article. Clinical Trial.
-
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.Addict Behav. 2013 May;38(5):2119-27. doi: 10.1016/j.addbeh.2013.01.024. Epub 2013 Feb 4. Addict Behav. 2013. PMID: 23435273 Free PMC article.
-
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.Am J Addict. 2003;12(s1):s69-s80. doi: 10.1111/j.1521-0391.2003.tb00497.x. Am J Addict. 2003. PMID: 14972781 Review.
-
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.J Stud Alcohol Suppl. 2005 Jul;(15):148-56; discussion 140. doi: 10.15288/jsas.2005.s15.148. J Stud Alcohol Suppl. 2005. PMID: 16223066 Review.
Cited by
-
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.Alcohol Clin Exp Res. 2011 Mar;35(3):523-31. doi: 10.1111/j.1530-0277.2010.01369.x. Epub 2010 Dec 8. Alcohol Clin Exp Res. 2011. PMID: 21143249 Free PMC article. Clinical Trial.
-
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.Alcohol Clin Exp Res. 2012 Dec;36(12):2141-9. doi: 10.1111/j.1530-0277.2012.01823.x. Epub 2012 May 2. Alcohol Clin Exp Res. 2012. PMID: 22551231 Free PMC article. Clinical Trial.
-
Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking.Addict Biol. 2019 Jan;24(1):28-39. doi: 10.1111/adb.12576. Epub 2017 Nov 2. Addict Biol. 2019. PMID: 29094432 Free PMC article.
-
An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol.Implement Sci. 2015 May 8;10:66. doi: 10.1186/s13012-015-0256-7. Implement Sci. 2015. PMID: 25951953 Free PMC article. Clinical Trial.
-
[Diagnosis, differential diagnosis and therapy of substance use disorders in general hospital (general section)].Neuropsychiatr. 2018 Jun;32(2):57-68. doi: 10.1007/s40211-017-0257-7. Epub 2018 Jan 11. Neuropsychiatr. 2018. PMID: 29327316 Review. German.
References
-
- Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology. 2004;173(12):32–40. - PubMed
-
- Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo controlled-placebo trial. American Journal of Psychiatry. 1999;156:1758–65. - PubMed
-
- Anton RF, O’Malley SS, Ciraulo D, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017. - PubMed
-
- Babor TF, Longabaugh R, Zweben A, Fuller RK, Stout RL, Anton RF, Randall CL. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol Suppl. 1994;12:101–11. - PubMed
-
- Baros AM, Latham PK, Monk DH, Voronin K. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Carroll Clin Exp. 2007;31:596–603. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AA011321/AA/NIAAA NIH HHS/United States
- P50 DA009241/DA/NIDA NIH HHS/United States
- UL1RR024139/RR/NCRR NIH HHS/United States
- K05 AA014906/AA/NIAAA NIH HHS/United States
- K05 DA00089/DA/NIDA NIH HHS/United States
- K0514906/PHS HHS/United States
- P50 DA09241/DA/NIDA NIH HHS/United States
- K05 DA000089/DA/NIDA NIH HHS/United States
- K05-AA014906/AA/NIAAA NIH HHS/United States
- K05 AA014715/AA/NIAAA NIH HHS/United States
- P50 AA-012870/AA/NIAAA NIH HHS/United States
- P50 AA012870/AA/NIAAA NIH HHS/United States
- R01 AA017173/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical